Dr Rimawi presents data at SABCS 2016 about the influence of added oestrogen deprivation to neo-adjuvant chemotherapy to with HR/HER2 positive breast cancer patients.

Overall, he describes additional therapy as not producing clinically significant results, which could be attributed to the chemotherapy regimen 'blunting' the clinical benefit of anti-oestrogens.

For more from this trial, Dr Rimawi spoke with ecancer, with a video interview coming soon.